Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5
January 29 2025 - 8:00AM
Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a
clinical-stage biotechnology company developing a new generation of
targeted antitumor virotherapies, is pleased to invite investors to
a webinar on February 5, 2025, at 4:15 p.m. ET.
The exclusive event, hosted by RedChip Companies, will feature
Calidi CFO Andrew Jackson and CSO Antonio F. Santidrian, PharmD.
PhD, who will share insight into the company’s groundbreaking
cell-based delivery platforms designed to protect, amplify, and
potentiate oncolytic viruses for enhanced cancer treatment.
Highlights will include overviews of Calidi’s lead programs, such
as its CLD-400 systemic platform targeting metastatic cancers,
CLD-201 for advanced solid tumors and CLD-101 for high-grade
glioma. A live Q&A session with the leadership team will follow
the presentation.
To register for the free webinar, please visit:
https://redchip.zoom.us/webinar/register/WN_qCp0OhjDSSaqiz3QsW9C_A#/registration
Questions can be pre-submitted to CLDI@redchip.com or online
during the live event.
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage
immuno-oncology company with proprietary technology designed to arm
the immune system to fight cancer. Calidi’s novel cell-based
platforms are utilizing potent allogeneic stem cells capable of
carrying payloads of oncolytic viruses for use in multiple oncology
indications, including high-grade gliomas and solid tumors.
Calidi’s clinical stage off-the-shelf, universal cell-based
delivery platforms are designed to protect, amplify, and potentiate
oncolytic viruses leading to enhanced efficacy and improved patient
safety. Calidi’s preclinical off-the-shelf enveloped virotherapies,
are designed to target disseminated solid tumors. This dual
approach can potentially treat, or even prevent, metastatic
disease. Calidi Biotherapeutics is headquartered in San Diego,
California. For more information, please
visit www.calidibio.com.
Forward-Looking StatementsThis press release
may contain forward-looking statements for purposes of the “safe
harbor” provisions under the United States Private Securities
Litigation Reform Act of 1995. Terms such as “anticipates,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intends,”
“may,” “might,” “plan,” “possible,” “potential,” “predicts,”
“project,” “should,” “towards,” “would” as well as similar terms,
are forward-looking in nature, but the absence of these words does
not mean that a statement is not forward-looking. These
forward-looking statements include, but are not limited to,
statements concerning upcoming key milestones (including the
reporting of interim clinical results and the dosing of patients),
planned clinical trials, and statements relating to the safety and
efficacy of Calidi’s therapeutic candidates in development. Any
forward-looking statements contained in this discussion are based
on Calidi’s current expectations and beliefs concerning future
developments and their potential effects and are subject to
multiple risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth or implied in
such forward-looking statements. These risks and uncertainties
include, but are not limited to, the risk that Calidi is not able
to raise sufficient capital to support its current and anticipated
clinical trials, the risk that early results of clinical trials do
not necessarily predict final results and that one or more of the
clinical outcomes may materially change following more
comprehensive review of the data, and as more patient data becomes
available, the risk that Calidi may not receive FDA approval for
some or all of its therapeutic candidates. Other risks and
uncertainties are set forth in the section entitled “Risk Factors”
and “Cautionary Note Regarding Forward-Looking Statements” in the
Company’s Registration Statements filed with the SEC on (i) Form
S-4 filed on August 2, 2023 and the corresponding prospectus filed
on August 4, 2023, and (ii) on Form S-1 filed on April 15, 2024,
and the Company’s periodic reports filed with the SEC on (i) Form
10-K filed on March 15, 2024, (ii) Form 10-Q filed on May 14, 2024,
(iii) Form 10-Q filed on August 13, 2024, and (iv) Form 10-Q filed
on November 12, 2024. These reports may be amended or supplemented
by other reports we file with the SEC from time to time.
Corporate Communications:Dave Gentry,
CEORedChip Companies, Inc.1-407-644-4256CLDI@redchip.com
Source: Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics (AMEX:CLDI)
Historical Stock Chart
From Feb 2025 to Mar 2025
Calidi Biotherapeutics (AMEX:CLDI)
Historical Stock Chart
From Mar 2024 to Mar 2025